Abstract
We present the data from 105 patients with primary epithelial ovarian cancer, who received up to 6 cycles of carboplatin (300 mg/m2) and cisplatin (100 mg/m2) as one treatment arm of a prospective randomized trial. Values for first-course carboplatin area-under-the-curve (AUC) were determined retrospectively. WHO grade 3-4 thrombocytopenia was found in 10% of patients with low AUC (AUC <4 mg/ml x min), but in 44.6% of patients with high AUC (AUC 4 mg/ml x min) (chi-square p<0.0001). No single case of ototoxicity was found in the low AUC group but in 12% of patients in the high AUC group (chi-square p=0.003). Determination of carboplatin AUC may prevent ototoxicity and severe thrombocytopenia for the first cycle of combined treatment with carboplatin and cisplatin.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Area Under Curve
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects*
-
Carboplatin / pharmacokinetics
-
Cisplatin / administration & dosage
-
Disease Progression
-
Double-Blind Method
-
Female
-
Humans
-
Middle Aged
-
Neoplasm Staging
-
Neoplasms, Glandular and Epithelial / drug therapy*
-
Neoplasms, Glandular and Epithelial / metabolism
-
Neoplasms, Glandular and Epithelial / mortality
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / mortality
-
Prospective Studies
-
Retrospective Studies
-
Survival Analysis
-
Time Factors
-
Treatment Outcome